Skip to Content

Saxenda Approval History

  • FDA approved: Yes (First approved December 23rd, 2014)
  • Brand name: Saxenda
  • Generic name: liraglutide
  • Dosage form: Injection
  • Company: Novo Nordisk
  • Treatment for: Obesity

Saxenda (liraglutide) is a once-daily glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.

Development History and FDA Approval Process for Saxenda

Dec 23, 2014Approval FDA Approves Saxenda (liraglutide [rDNA origin] injection) for Obesity
Sep 11, 2014FDA Advisory Committee Votes 14-1 in Favor of Saxenda (liraglutide) for Obesity

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.